Forty patients is a small number to carry a regulatory filing, but Vanda’s Phase III result for tasimelteon in Delayed Sleep-Wake Phase Disorder is cleaner than the enrollment count suggests. In the 20-patient active arm, sleep onset shifted 42.5 minutes earlier over 28 days; the placebo arm moved 5.4 minutes, producing a 37.1-minute treatment difference that cleared statistical significance at p=0.022. Four in ten people with DSWPD have a body clock stably fixed hours behind conventional schedules, not a preference for late nights, and the disorder affects an estimated 0.5 to 4.1 million U.S. adults. That population has long been managed without an FDA-approved option specifically for the condition.
The responder split sharpens the picture further. Sixty percent of tasimelteon-treated participants advanced sleep onset by at least 30 minutes, versus 15% on placebo, a difference that reached p=0.008 on Fisher’s exact test. Vanda plans to file a supplemental NDA anchored on this study, supplemented by prior work in related circadian disorders and more than a decade of safety data from two existing approved indications: Non-24-Hour Sleep-Wake Disorder (2014) and nighttime sleep disturbances in Smith-Magenis Syndrome (2020). The same 20 mg dose, same molecule, same mechanism. That continuity limits FDA’s exposure to novel safety questions, which is about the best structural argument a small-molecule sNDA can make.
The commercial context adds pressure to get this right. HETLIOZ net product sales fell 7% in 2025 to $71.4 million, then dropped another 24% year-over-year in Q1 2026 to $15.9 million. A third approved indication would give prescribers a reason to reach for the drug in a population that is substantially larger than either of the current label populations. DSWPD’s comorbidity with psychiatric disorders also means the patient base overlaps heavily with practices that already see these patients regularly.
The trial’s 26-site, five-year enrollment timeline to reach 43 evaluable patients signals how hard this population is to diagnose and recruit. FDA will weigh whether a 40-patient controlled dataset is sufficient to support broad labeling, or whether it will request additional evidence before approval. That question, not the p-value, is the one to watch as Vanda moves into pre-submission discussions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
